References
- AdamHJLaingNMKingCRLulashnykBHobanDJZhanelGGIn vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolatesAntimicrob Agents Chemother2009534915492019738018
- ChenYHLiuCYLuJJKingCHHsuehPRIn vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in TaiwanJ Antimicrob Chemother2009641226122919833635
- LauderdaleTLShiauYRLaiJFChenHCKingCHComparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolatesAntimicrob Agents Chemother2010541338134220065058
- van RensburgDJPerngRPMithaIHEfficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumoniaAntimicrob Agents Chemother2010544098410620660689
- QinXHuangHReview of nemonoxacin with special focus on clinical developmentDrug Des Devel Ther20148765774
- GuoBWuXZhangYSafety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral dosesClin Drug Investig201232475486
- LinLChangLWTsaiCYDose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteersAntimicrob Agents Chemother20095440541019884368
- ChungDTTsaiCYChenSJMultiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteersAntimicrob Agents Chemother20105441141719884374
- ZhangYFDaiXJWangTEffects of an Al3+− and Mg2+− containing antacid, ferrous sulfate, and calcium carbonate on the absorption of nemonoxacin (TG-873870) in healthy Chinese volunteersActa Pharmacol Sin2014351586159225327812
- LandersdorferCBKirkpatrickCMKinzigMCompetitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecidBr J Clin Pharmacol20106916717820233180
- LandersdorferCBKirkpatrickCMKinzigMCompetitive inhibition of renal tubular secretion of gemifloxacin by probenecidAntimicrob Agents Chemother2009533902390719564368
- NakashimaMUematsuTKosugeKSingle- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humansAntimicrob Agents Chemother199539263526408592993
- FishDNChowATThe clinical pharmacokinetics of levofloxacinClin Pharmacokinet1997321011199068926
- MulgaonkarAVenitzJGründemannDSweetDHHuman organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobialsAntimicrob Agents Chemother2013572705271123545524
- AllenABirdNDixonREffect of cimetidine on the pharmacokinetics of oral gemifloxacin in healthy volunteersClin Drug Invest200121519526
- MulgaonkarA1VenitzJSweetDHFluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transportersExpert Opin Drug Metab Toxicol2012855356922435536
- StassHSachseREffect of probenecid on the kinetics of a single oral 400 mg dose of moxifloxacin in healthy male volunteersClin Pharmacokinet200140Suppl 1717611352445
- SörgelFGrannemanGRStephanULockeCEffect of cimetidine on the pharmacokinetics of temafloxacinClin Pharmacokinet199222Suppl 175821319874
- MisiakPM1EldonMAToothakerRDSedmanAJEffects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacinJ Clin Pharmacol199313353568429114